Alpha-2 adrenergic receptor polymorphisms
The present invention includes polymorphisms in nucleic acids encoding the alpha-2B, alpha-2A, and alpha-2C adrenergic receptor and expressed alpha-2B, alpha-2A and alpha-2C adrenergic receptor molecule. The invention also pertains to methods and molecules for detecting such polymorphisms. The invention further pertains to the use of such molecules and methods in the diagnosis, prognosis, and treatment of diseases such as cardiovascular and central nervous system disease.
1. A method of genotyping or detecting a polymorphic site an alpha-2C adrenergic receptor gene comprising:
(a) obtaining an isolated polynucleotide from a human that encodes an alpha-2C adrenergic receptor molecule or a fragment thereof wherein said fragment comprises nucleotide positions 963 to 976 of SEQ ID NO: 40, or a complete complement thereof, or a complete complement of said fragment; and
(b) screening the isolated polynucleotide, or said fragment thereof, or said complete complement thereof, or said complete complement of said fragment for the presence or absence of a polymorphic site comprising SEQ ID NO: 41, or a complete complement thereof, wherein the presence corresponds to the wild-type sequence and the absence corresponds to a deletion of 964 to 975 of SEQ ID NO: 40.
2. A method according to claim 1 , wherein the polymorphic site is detected using a technique selected from a group consisting of: terminator sequencing, restriction digestion, allele-specific polymerase reaction, single-stranded conformational polymorphism analysis, genetic bit analysis, temperature gradient gel electrophoresis, ligase chain reaction, and ligase/polymerase genetic bit analysis.
3. A method according to claim 1 , wherein the polymorphic site is detected by employing nucleotides with a detectable characteristic selected from the group consisting of inherent mass, electric charge, electron spin, mass tag, radioactive isotope, dye, bioluminescence, chemiluminescence, light scattering/phase shifting and fluorescence.